Amyloid Hypothesis vs Tau Hypothesis in Alzheimer’s Disease
In a recent scientific commentary, Brenda Knox at StressMarq delves into the complex interplay between amyloid-beta plaques and tau neurofibrillary
Read moreIn a recent scientific commentary, Brenda Knox at StressMarq delves into the complex interplay between amyloid-beta plaques and tau neurofibrillary
Read moreStressMarq Biosciences, a prominent leader in the field of neurodegenerative disease research products, is excited to announce its participation in
Read moreResearchers have devised a novel human 3D model for Alzheimer’s Disease, enabling the study of immune cell involvement in the
Read moreSeelos Therapeutics, Inc., a clinical-stage biopharmaceutical company specializing in therapies for central nervous system disorders and rare diseases, has unveiled
Read moreThe Biosimilar Tyruko® has been approved for all indications of reference medicine, as the first and only biosimilar to treat
Read moreStressMarq manufactures and offers a comprehensive range of Alzheimer’s Disease Research Products. StressMarq’s product range includes Antibodies, Proteins, Immunoassays, Small
Read moreThe Synuclein-α (Phospho-Ser129) Colorimetric Cell-Based ELISA Kit is a user-friendly and highly sensitive assay designed to detect the protein expression
Read moreStressMarq provides a cutting-edge selection of Amyloid Beta Pre-formed Fibrils (PFFs), Oligomers, and Monomers specifically designed to facilitate advanced neurodegenerative
Read moreStressMarq has developed unique Superoxide Dismutase 1 (SOD1) Pre-formed Fibrils (PFFs) and monomers for neurodegenerative disease research, particularly valuable for
Read moreStressMarq has developed unique Transthyretin (TTR) Filaments and Monomers designed to propel research on TTR and its association with amyloid
Read more